Variable response to the biological inhibition of platelets by abciximab in patients subjected to percutaneous coronary angioplasty

Revista Espanola de Cardiologia

Volumn 54, Issue 11, 2001, Pages 1256-1263

  Galeote, Guillermo ^a   Sobrino, Nicolés ^a   Calvo, Luis ^a   Hussein, Monzer ^a   Sobrino, José A ^a   López Pastor, Ángela ^a   Cárcamo, Cristina ^a   García Muñoz, Soledad ^a   Férnandez Chacón, José L ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Coronary angioplasty; Platelet; Platelet inhibition aggregation

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; HEPARIN; PADGEM PROTEIN; THROMBOCYTE ACTIVATING FACTOR; TICLOPIDINE; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BLOOD CLOTTING PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG EFFECT; DRUG RESPONSE; FEMALE; HEMOSTASIS; HUMAN; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRACTICE GUIDELINE; PROTEIN EXPRESSION; RISK ASSESSMENT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOSIS; TIME; DRUG ANTAGONISM; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY; THROMBOCYTE ADHESIVENESS; THROMBOCYTE AGGREGATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADENOSINE DIPHOSPHATE; ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSPECTIVE STUDIES;

EID: 0034747237     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-8932(01)76494-9     Document Type: Article

References (61)

1. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty
2. Platelet glycoprotein IIb/IIIa receptor blockade in low -dose heparin during percutaneous coronary revascularization
3. Multicenter, randomized, double-blind placebo controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrilin in elective coronary intervention
4. Randomized placebo-controlled trial of eptifibatide on complications of percutaneous coronary intervention. Impact-II
5. Effects of platelet glycoprotein blockade whit tirofibån on adverse cardiac events in patients whit unstable angina or acute myocardial infarction undergoing angioplasty
6. The platelet membrane glycoprotein IIb/IIIa complex
7. Platelet GpIIb/IIIa blockers
8. Balloon angioplasty: Natural history of pathophysical response to injure in a pig model
9. Coronary thrombosis: Pathogenesis and clinical manifestations
10. Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction
11. Monoclonal antibody to P-Selectin (PB1,3) protects against myocardial reperfusion injury in the dog
12. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents
13. Preclinical developement of c7E3 Fab, a mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GpIIb/IIIa receptors with observations on the inmunogenicity of c7E3 Fab in humans
14. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein IIb/IIIa receptor antagonist in healthy men
15. Inmediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during pecutaneous coronary intervention
16. Platelet glycoprotein IIb/IIIa antagonists
17. Attainment and Maintenance of platelet inhibition through standard dosing of Abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention
18. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor -activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of IIb/IIIa receptors
19. Rapid assesment of platelet function with a modified whole-blood aggregometer in pecutaneous trasluminal coronary angioplasty patients receiving anti Gp IIb/IIIa therapy
20. Time corse, magnitude, and cosistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention
21. Monitoring platelet GpIIb/IIIa antagonist therapy
22. Applications of antiplatelet monitoring in catheterization laboratory
23. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironement of the platelet glycoprotein IIb/IIIa complex
24. Circulating platelets show increased activation in patients wiht acute cerebral ischemia
25. Caractherization of an in vitro platelet function analizer PFA-100
26. PFA-100 system: A new method for assesment of platelet disfunction
27. Aggregation of blood platelets by adenosine diphosphate and its reversal
28. The effect of ticlopidine administration to humans on the binding of adenosine diphosphate to blood platelets
29. Ticlopidine: A promise for the prevention and treatment of thrombosis and its complications
30. Evaluation of platelet function by flow cytometry
31. Monoclonal antibodies to platelet GPIIb/IIIa as antithrombotic agents
32. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antplatelet antibody Fab 7E3 in high-risk coronary anioplasty
33. Randomized trial of a GPIIb/IIIA platelet receptor blocker in refractory unstable angina
34. The platelet membrane glycoprotein IIb/IIa complex
35. Abciximab: An update review of its use in ischemic heart disease
36. Inhibitors of the platelet glycoprotein IIb/IIIa receptor as conjunctive therapy for coronary thrombolysis
37. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reoclussion after reperfusion with recombinant tissue type plasminogen activator
38. Rapid and sustained coronary artery recanalization with reecombinant tissue type plasminogen activator and monoclonal anti-platelet GPIIb/IIIa antibody in a dog model
39. Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases
40. Immunofluorescente localization of adhesive glycoprotein in resting and thrombin-stimulated platelet
41. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor activating peptide in patients treated with bolus chimeric 7E3 fab: Implications for inhibition of the internal GPIIb/IIIa receptors
42. Expression of inducible nitric oxide synthase in the carotid of rats after endothelial skinning: The effects of platelets and treatment with abciximab
43. Incomplete inhibition of platelet aggregation and glycoprotein IIb/IIIa receptor blockade by abciximab. Importance of internal pool of glycoprotein IIb/IIIa receptors
44. Shear induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe estenosis
45. Shear-induced aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary
46. Direct demostration of radiolabeled von Willebrand factor binding to platelet glycoprotein Ib and IIb/IIIa in the presece of shear stress
47. Distinct mechanisms of platelet aggregation as aconsecuence of different shear flow conditions
48. Platelet and Shear Sterss
49. Von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterona sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction
50. Assesment of platelet function assays
51. Pharmacodynamic profile of short term abciximab treatment demostrates prolonged platelet inhibition with gradual recovery from GPIIb/IIIa receptor blockade
52. Use of PFA-100 apparatus to asses platelet function in patients undergoing PTCA during and after infusion of c7E3 Fab in the presence of other antiplatelet agents
53. Properties of GMP-140, and inducible granule membrane protein of platelets and endothelium
54. Usefulness of soluble and surface bound P-selectine on platelets in detecting heightened platelet activity in patients wiht congestive hearth failure
55. Significance of soluble P-selectine, von Willebrand factor, and other adhesion molecules in hipercholesterolemia and peripheal artery disease
56. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA
57. Platelet function in acute myocardial infarction treated with direct angioplasty
58. Platelet activation in patients after an acute coronary syndrome: Results from the TIMI-12 trial, Thrombolysis in Myocardial Infarction
59. Role of selectins in leucocite adhesion to platelets and endothelium
60. A new role for P-selectin in shear-induced platelet aggregation
61. Assessing the optimal level of platelet inhibition with GPIIb/IIIa inhibitors in patients undergoing coronary intervention. Rationale and desing of the GOLD study